Janssen Reports Positive Topline Phase 2 Results for Nipocalimab in Pregnant Individuals at High Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
SPRING HOUSE, PENNSYLVANIA, February 6, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the proof-of-concept Phase 2 open-label UNITY clinical trial for the treatment of pregnant adults at high risk for severe hemolytic disease of the fetus and newborn (HDFN). HDFN is a serious and rare condition which can cause life-threatening anemia in the fetus. It occurs when the blood types of a pregnant individual and their fetus are incompatible.1 The trial met the primary endpoint, with the majority of pregnant patients who received nipocalimab achieving a live birth at or after the gestational age (GA) of 32 weeks, without the need for an intrauterine transfusion (IUT) throughout their entire pregnancy. During the treatment period of approximately 20 weeks, nipocalimab demonstrated a safety profile that supports further development of the treatment in HDFN.Nipocalimab was granted Fast Track designation in July 2019 and orphan drug status in June 2020 by the U.S. Food and Drug Administration (FDA), and orphan medicinal product designation by the European Medicines Agency in October 2019 for HDFN.“These early results represent an important step towards delivering a potential medication for expectant mothers at high risk of severe HDFN, and we are encouraged by what this treatment could mean for families affected by this potentially devastating disease. I would like to thank our patients and investigators for their ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Latest News Source Type: news
More News: Allergy & Immunology | Anemia | Arthritis | Autoimmune Disease | Brain | Cancer & Oncology | Cardiology | Cardiovascular | Child Development | Children | CIDP | Clinical Trials | European Medicines Agency (EMA) | Food and Drug Administration (FDA) | Health Management | Heart | Hematology | Hypertension | Infectious Diseases | Learning | Legislation | Lupus | Myasthenia Gravis | Nanotechnology | Neurology | Neuroscience | OBGYN | Perfusion | Pharmaceuticals | Pregnancy | Premature Birth | Pulmonary Hypertension | Rare Diseases | Rheumatoid Arthritis | Rheumatology | Science | Study | Universities & Medical Training | USA Health | Vaccines | Women